Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Motixafortide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Motixafortide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
July 23, 2024
Lead Product(s) : Motixafortide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Motixafortide,G-CSF
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : BioLineRx
Deal Size : $279.6 million
Deal Type : Licensing Agreement
BioLineRx Entered Exclusive License Agreement with Motixafortide in Asia, Advised by MSQ Ventures
Details : Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Product Name : Aphexda
Product Type : Peptide, Unconjugated
Upfront Cash : $29.6 million
October 31, 2023
Lead Product(s) : Motixafortide,G-CSF
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : BioLineRx
Deal Size : $279.6 million
Deal Type : Licensing Agreement
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : YuTuo (zimberelimab) is the world's first fully human anti-PD-1 monoclonal antibody in market developed by the transgenic rat platform, OmniRat, which is investigated for the treatment of metastatic cervical cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 06, 2023
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLS-012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 07, 2023
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GLS-012 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 18, 2023
Lead Product(s) : GLS-012
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimberelimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 13, 2023
Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 05, 2023
Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hodgkin Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 26, 2022
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zimberelimab is a fully human monoclonal antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : Zimberelimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Ligand Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer
Details : GLS-010 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Uterine Cervical Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 04, 2019